|
|
Position:
Bioanalytical Scientist/Senior Scientist, Nonclinical Development
Employer:
Olema Oncology
Description:
Olema Oncology (NASDAQ: OLMA) is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Our lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. We are supported in our mission by experienced and accomplished scientists and board members, leading healthcare investors, and some of the most innovative pharma companies. For more information about the company please visit www.olema.com.
The Role:
The Bioanalytical Scientist/Senior Scientist will be an essential part of Olema’s drug discovery and development efforts working closely with multiple departments within Olema. As a member of the Nonclinical Development department, this individual will address all bioanalytical deliverables spanning biology, medicinal chemistry, pharmacology, DMPK and toxicology functions. This role is a laboratory based and is located in San Francisco, CA. This individual will work independently under minimal supervision and is proactive in suggesting and implementing new analytical technology and workflow improvements. The exact level will be determined based on candidate’s experience. This role reports to the Senior Director of Nonclinical Development.
This is a fantastic opportunity for a talented Bioanalytical Scientist to join a company with an industry leading Board of Directors and Management team, and roll up their sleeves to build an innovative women’s oncology company with significant potential to transform breast cancer treatments.
What You Will Do:
- Design and execute specific bioanalytical and ADME/PK (in vitro and in vivo) studies for multiple drug discovery and development programs.
- Develop bioanalytical assays (LC-MS/MS) for analysis of drug and/or metabolite concentrations in blood, plasma, urine, and tissue samples.
- Interpret the bioanalytical data, calculate PK parameters where it is appropriate, and prepare bioanalytical reports.
- Run in vitro ADME studies such as metabolic stability assays in hepatocyte, liver microsomes and S9, plasma protein binding, and blood to plasma partitioning etc.
- Perform metabolism studies in different species using liver microsomes and hepatocytes including metabolite identification.
- Present the bioanalytical and PK data in the stakeholder team meetings.
- Collaborate with various functions to develop and optimize bioanalytical technologies/strategies.
- Utilization and management of in-house LC/MS equipment
Qualifications/Experience:
- Ph. D. in chemistry, analytical chemistry, biochemistry, pharmaceutical science, or related scientific discipline or BS/MS with extensive (7+ years) biopharmaceutical industry experience. The exact job level will commensurate to candidate’s overall skills and experience.
- In-depth knowledge of bioanalysis, drug metabolism, metabolite identification, CYP450 induction/inhibition assays, drug transporters, and ADME/PK from a variety of in vitro and in vivo studies.
- Hands-on experience with in vitro ADME assays and in vivo bioanalytical studies including evaluation of physiochemical properties and pharmacokinetic analysis.
- Experience operating, troubleshooting, and maintaining LC-MS/MS and related analytical equipment.
- Excellent communication, organization, and presentation skills.
- Ability to work independently and collaboratively in a team setting in a fast-paced environment.
Location:
San Francisco, CA
Contact:
gpalanisamy@olema.com
Post Date:
7/21/2021 12:00:00 AM
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Submit a Text Ad
|